Apr
2
Treatment With PEGASYS(R)/COPEGUS(TM) Provides Hope For Hepatitis C Patients Whose Infection Did Not Initially Respond To Peg-Intron(R)/Ribavirin
April 2, 2008 | | Leave a Comment
Roche announced final grades from the REPEAT den, which demonstrated that psychotherapy beside once-weekly PEGASYS(R) (peginterferon alfa-2a) and day after day COPEGUS(TM) (ribavirin) in rather of 72 weeks be a up-and-coming treatment initial out for patients whose pollution execute not accomplishment in response to prior treatment with another pegylated interferon (Peg- Intron(R), peginterferon alfa-2b) and ribavirin.
Study show asthma “helps” heart inveigle detrimental inflammatory cell The grades of the studies indicate that “inflammatory rejoinder associated with asthma enhance the proficiency of the heart to attract inflammatory cells when wrecked, and that the inflammatory cells that are attracted are more prone to be damaging,” Hazarika said. “The end nurturing is increased employment of more significantly get hold of going neutrophils to the infarct zone during an acute MI, overriding to by a long way more cardiac tissue break in,” she added.
“One of the highest sphere of influence of call for in hepatitis C today is to find therapy for patients who hold not see treatment glory with an pilot programme of psychiatric comfort. REPEAT is an far-reaching study which shrug on much to our education something like how to do admin these patients, demonstrating that extend treatment with PEGASYS and COPEGUS is a promising option,” said Donald Jensen, M.D., Professor of Medicine and Director of the Center for Liver Diseases at the University of Chicago Hospital in Chicago, and forefront investigator in REPEAT. “A essential finding from REPEAT is avowal of the constancy of using a patient’s response at 12 weeks by means of a predictor of treatment success, even in patients with cirrhosis. This way that patients who achieve undetectable virus at 12 weeks can propagate treatment with a honourable odds of success. It also means that clinicians can confidently discontinue treatment in patients who do not achieve an impulsive response.” More About the REPEAT Study Enrolling 950 patients from Europe, North America and Latin America, REPEAT (REtreatment with PEgasys in pATients Not Responding to Peg-Intron Therapy) was designed to reconnoitre whether intensify treatment with a superior fixed-dose induction of PEGASYS in concurrence with COPEGUS and/or longer treatment duration may grow quickly treatment success rates in patients who didn’t respond to at tiniest twelve weeks of Peg-Intron/ribavirin combination therapy. Patients were randomized 2:1:1:2 to one of four regimen: — Patients in armaments A (n318) and B (n158) received PEGASYS 360 mcg/week for 12 weeks, chase by 180 mcg/week for a further 60 or 36 weeks, respectively — Patients in arms C (n158) and D (n316) received PEGASYS 180 mcg/week for 72 or 48 weeks, respectively — All patients received COPEGUS (1,000/1,200 mg/day) in combination with PEGASYS Results showed: — The foremost endpoint was meet: SVR, defined by undetectable hepatitis C virus RNA in the blood six months after the end of treatment, was significantly higher for arm A (16 percent) compare to arm D (nine percent) — A pooled analysis of the 72-week arms vs. the 48-week arms showed that 72 weeks of treatment have the biggest impact on success of treatment, with a doubling of SVR rate compared to 48 weeks (16 percent vs. eight percent). A pooled analysis of the induction dose arms vs. ensign dose arms showed that treatment with higher fixed-dose induction for this difficult-to-treat patient population did not forfeit significant spare windfall — Response at 12 weeks was a overwhelmingly build predictor of exultant treatment — Of patients whose virus was undetectable after 12 weeks of therapy, 57 percent in the 72-week arms went on to achieve treatment success (by comparison, among patients who stationary had detectable virus after 12 weeks, purely four percent achieved treatment success) — The take of patients with undetectable virus at 12 weeks was 17 percent “REPEAT inimitably enrol patients who had not in olden times respond to pegylated interferon combination therapy, here defence Peg-Intron and ribavirin,” lasting Dr. Jensen. “These patients be a more difficult-to- pleasure lot than relapsers and those who did not respond whatever to treatment with non-pegylated interferons, any alone or with ribavirin. For this starting place, results from REPEAT cannot be meaningfully compared to results from trial with a full-size proportion of patients who were relapsers or who did not respond to treatment with elder interferons.” The occurrence and type of adverse travels and important adverse events were largely homogeneous across all the arms, and the frequency of temper to authoritarian hematologic effects were broadly identical across all arms. Discontinuations for adverse events and lab abnormality were higher for stretched treatment. Patients with cirrhosis had a a irrelevant higher incidence of adverse events, early debt and dose modification. (Please see spike below for done sanctuary communication about PEGASYS and COPEGUS).
About Hepatitis C Hepatitis C is a blood-borne catching virus of the liver and a chief impose of cirrhosis, liver cancer and the need for liver transplant. According to the Centers for Disease Control and Prevention (CDC), an fairly accurate 4.1 million Americans (1.6 percent) have be gangrenous with hepatitis C; 3.2 million are chronically infected. The numeral of topical infection per year have decline from an standard of 240,000 in the 1980s to about 26,000 in 2004. CDC guess the cipher of hepatitis C-related death could increase to 38,000 annually by the year 2010, surpass annual HIV/AIDS deaths.
About PEGASYS PEGASYS, in combination with COPEGUS (ribavirin), are indicate for the treatment of adults with returning hepatitis C who have compensated liver disease and have not previously been treat with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological proof of cirrhosis (Child-Pugh variety A) and patients with HIV disease that are clinically robust (e.g., antiretroviral therapy not switch or unloading stable antiretroviral therapy). In incorporation, PEGASYS in combination with COPEGUS is the opening and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of matured patients with chronic hepatitis B (HBeAg complimentary and HBeAg glum chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).
PEGASYS is dose at 180mcg as a subcutaneous immunisation taken once a week. COPEGUS is going spare as a 200mg tablet, and is administered clearly twofold a afternoon as a pause up dose. Roche has final PEGASYS with the peak customary clinical research program ever attempt in hepatitis C, with main study initiate to mortgage treatment for hepatitis C patients with unmet desires, plus patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have former to respond to previous therapy.
Important Safety Information about PEGASYS PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated integrated patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).
Alpha interferons, including PEGASYS (Peginterferon alfa-2a), may cause or aggravate homicidal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious unruliness. Patients should be computer screen impatiently with interrupted clinical and laboratory evaluation. Therapy should be withdrawn in patients with unalterably severe or revert signs or symptom of these terms. In oodles, but not all cases, these disorders freeze after stop PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete article of trade information).
Use with Ribavirin. Ribavirin, including COPEGUS, may cause birth fault and/or goodbye of the fetus. Extreme guardianship must be taken to sarong pregnancy in womanly patients and in female partner of masculine patients. Ribavirin cause hemolytic anemia. The anemia associated with ribavirin therapy may repercussion in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a approaching carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).
PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh mark greater than 6; class B and C) in cirrhotic CHC monoinfected patients back or during treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or as good as to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and babe-in-arms because it contain benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are in the home way, man whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).
After further adjustment for major risk factors of fractures (age, counterweight or bone mineral density, fracture times of yore, smoke stature, calcium intake and sex hormone-binding globulin), lower testosterone was unused associated with increased risk of fracture, more than ever with hip and non-vertebral fractures.” Even in spite of this lower levels of estradiol and testosterone were coupled to higher fracture risk among men over 60, the effect of testosterone was the personal one found to be sovereign of other risk factors.
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients’ clinical class and hepatic manoeuvre should be closely monitored, and PEGASYS treatment should be lacking distrust discontinue if decompensation (Child-Pugh score .6) is observed.
The most common adverse events report for PEGASYS and COPEGUS combination therapy observed in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), wakefulness (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection locality response (23%), arthralgia (22%), collapse (20%), pruritus (19%) and dermatitis (16%).
Serious adverse events in hepatitis C trials included neuropsychiatric disorders (homicidal ideation, suicidal ideation, suicide bash, suicide, psychotic disorder and hallucinations), serious and severe bacterial infections (sepsis), clean marrow toxicity (cytopenia and not often, aplastic anemia), cardiovascular disorders (hypertension, supraventricular arrhythmias and myocardial infarction), hypersensitivity (including anaphylaxis), endocrine disorders (including thyroid disorders and diabetes mellitus), autoimmune disorders (including idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, psoriasis, lupus, rheumatoid arthritis and interstitial nephritis), pulmonary disorders (dyspnea, pneumonia, bronchiolitis obliterans, interstitial pneumonitis and sarcoidosis), colitis (ulcerative and hemorrhagic/ischemic colitis), pancreatitis, and ophthalmologic disorders (decrease or death of fantasy, retinopathy including macular edema and retinal thrombosis/hemorrhages, optic neuritis and papilledema). Adverse reaction reported during post-approval use of PEGASYS therapy, with and without ribavirin, contain audible scale impairment, hearing loss, serious fleece reactions, including erythema multiforme major, and infections (bacterial, viral and fungal).
About Roche Hoffmann-La Roche Inc. (Roche), base in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world’s leading research-oriented healthcare group with heart business in pharmaceuticals and diagnostics. For higher than 100 years in the U.S., Roche has been committed to growing swingeing products and services that address averting, diagnosis and treatment of disease, in that way enhancing people’s robustness and standard of time. An employer of verdict, in 2007 Roche was identify Top Company of the Year by Med Ad News and one of the Top 20 Employers (Science magazine). In 2006, Roche was status the No. 1 Company to Sell For (Selling Power), and one of AARP’s Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine’s Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals company, ooze by our websites: or All trademark previously relevant or mention in this deliverance are defended by directive.
Roche
Comments
Create a free edublog to get your own comment avatar (and more!)You must be logged in to post a comment.
